Adverse events associated with dasatinib experienced by at least 10% of patients
| . | No. (%) of patients at 8 months' follow-up . | |
|---|---|---|
| Grades 1-4 . | Grades 3-4 . | |
| Diarrhea | 11 (31) | 3 (8) |
| Pyrexia | 9 (25) | 1 (3) |
| Nausea | 8 (22) | 0 |
| Asthenia | 7 (19) | 3 (8) |
| Pleural effusion | 7 (19) | 1 (3) |
| Rash | 6 (17) | 1 (3) |
| Weight decrease | 6 (17) | 0 |
| Peripheral edema | 6 (17) | 0 |
| Dyspnea | 5 (14) | 1 (3) |
| Headache | 5 (14) | 0 |
| Febrile neutropenia | 4 (11) | 4 (11) |
| Fatigue | 4 (11) | 0 |
| Vomiting | 4 (11) | 0 |
| . | No. (%) of patients at 8 months' follow-up . | |
|---|---|---|
| Grades 1-4 . | Grades 3-4 . | |
| Diarrhea | 11 (31) | 3 (8) |
| Pyrexia | 9 (25) | 1 (3) |
| Nausea | 8 (22) | 0 |
| Asthenia | 7 (19) | 3 (8) |
| Pleural effusion | 7 (19) | 1 (3) |
| Rash | 6 (17) | 1 (3) |
| Weight decrease | 6 (17) | 0 |
| Peripheral edema | 6 (17) | 0 |
| Dyspnea | 5 (14) | 1 (3) |
| Headache | 5 (14) | 0 |
| Febrile neutropenia | 4 (11) | 4 (11) |
| Fatigue | 4 (11) | 0 |
| Vomiting | 4 (11) | 0 |